Live Breaking News & Updates on Centrally Calculated

Stay updated with breaking news from Centrally calculated. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial

/PRNewswire/ Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at. ....

United States , Edna Kaplan , Paula Schwartz , Jessica Breu , Andreas Muehler , Daniel Vitt , Exchange Commission , World Health Organization , Rx Communications Group , Immunic Inc , Centrally Calculated , Chief Executive Officer , Chief Medical Officer , Trial Synopsis , Mayo Clinic , Private Securities Litigation Reform Act , Annual Report , Quarterly Report , Investor Relations , ஒன்றுபட்டது மாநிலங்களில் , எட்னா கபிலன் , பால ஸ்க்வார்ட்ஸ் , ஜெசிகா ப்ரூ , டேனியல் விட் , பரிமாற்றம் தரகு , உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந் ,

DGAP-News: Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial

DGAP-News: Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial
Table: IMU-838 Shows Acceleration of Time to Clinical Improvement
High-risk patients and patients aged over 65 years experienced a more substantial treatment benefit from IMU-838 than in the general patient population:
- The 75% probability
[5] to reach clinical improvement (based on investigator assessment) was accelerated by 3.8 days in IMU-838 treated high-risk patients
[6], as compared to placebo (FAS).
- The 75% probability
[5] to reach clinical improvement (based on investigator assessment) was accelerated by 4.8 days in IMU-838 treated elderly patients (65 years or older), as compared to placebo (FAS). ....

United States , Paula Schwartz , Edna Kaplan , Jessica Breu , Andreas Muehler , Daniel Vitt , Exchange Commission , World Health Organization , Rx Communications Group , Immunic Inc , Distribution Services , Announces That Oral Treatment , Clinical Activity , Multiple Secondary Endpoints , Including Clinically Meaningful Improvements , Clinical Recovery , Clinical Improvement , Very Low Rates , Serious Complications , Hospitalized Patients With Moderate , Risk Patients , Patients Aged Over , More Substantial Treatment Effect , Anti Inflammatory Effect Observed , More Effective Reduction , C Reactive Protein ,